Matthias Staehelin

JFG Life Sciences Stiftung der Universität Basel engages in the promotion of innovation transfer in the field of life sciences and related areas. It also supports knowledge and technology transfer at the University of Basel. The company was founded on December 20, 2018 and is headquartered Basel, Switzerland.

Nuclidium AG is a private company located in Switzerland that is revolutionizing precision oncology by developing copper-based radiopharmaceuticals for targeted cancer treatment and diagnosis. The Swiss company's product portfolio utilizes the unique properties of copper to achieve improved safety and efficacy with advantageous economics for hospitals and patients. The company overcomes supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. Nuclidium's diverse and interdisciplinary team is focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients. The company's flexible CutraCeTM platform combines copper radiometals with highly specific cancer-targeting molecules to rapidly develop novel diagnostic and therapeutic programs. Nuclidium's differentiated "diagnostic to therapeutic" approach de-risks their development pathway.